Major bleeding caused by warfarin in a genetically susceptible patient

Aharon Bloch; Eldad Ben-Chetrit; Mordechai Muszkat; Yoseph Caraco

doi:10.1592/phco.22.1.97.33491

Major bleeding caused by warfarin in a genetically susceptible patient

Aharon Bloch, Eldad Ben-Chetrit, Mordechai Muszkat, Yoseph Caraco^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

A 90-year-old woman was hospitalized for gastrointestinal bleeding. Although she had been receiving only warfarin 5 mg/day, her international normalized ratio (INR) was 66. Warfarin was discontinued, and her INR fell to 3.7 after transfusion of fresh-frozen plasma. However, it rose again spontaneously to 7.5. Eleven days after the last dose of warfarin had been administered, it was still detectable in the patient's plasma, indicating that impaired warfarin clearance may have caused an enhanced anticoagulation effect. Genetic analysis of the cytochrome P450 (CYP) isoenzyme 2C9, which mediates the major deactivating pathway of S-warfarin, revealed that the patient was a compound heterozygote carrying two variant alleles: CYP2C9*2 and CYP2C9*3. The patient's enhanced sensitivity to warfarin 5 mg/day can be ascribed to decreased clearance of S-warfarin secondary to genetic alteration of the gene encoding CYP2C9, resulting in a life-threatening complication.

Original language	American English
Pages (from-to)	97-101
Number of pages	5
Journal	Pharmacotherapy
Volume	22
Issue number	1
DOIs	https://doi.org/10.1592/phco.22.1.97.33491
State	Published - 2002
Externally published	Yes

Access to Document

10.1592/phco.22.1.97.33491

Cite this

@article{8317dafde65f4ebb86a09e184edbafa5,

title = "Major bleeding caused by warfarin in a genetically susceptible patient",

abstract = "A 90-year-old woman was hospitalized for gastrointestinal bleeding. Although she had been receiving only warfarin 5 mg/day, her international normalized ratio (INR) was 66. Warfarin was discontinued, and her INR fell to 3.7 after transfusion of fresh-frozen plasma. However, it rose again spontaneously to 7.5. Eleven days after the last dose of warfarin had been administered, it was still detectable in the patient's plasma, indicating that impaired warfarin clearance may have caused an enhanced anticoagulation effect. Genetic analysis of the cytochrome P450 (CYP) isoenzyme 2C9, which mediates the major deactivating pathway of S-warfarin, revealed that the patient was a compound heterozygote carrying two variant alleles: CYP2C9*2 and CYP2C9*3. The patient's enhanced sensitivity to warfarin 5 mg/day can be ascribed to decreased clearance of S-warfarin secondary to genetic alteration of the gene encoding CYP2C9, resulting in a life-threatening complication.",

author = "Aharon Bloch and Eldad Ben-Chetrit and Mordechai Muszkat and Yoseph Caraco",

year = "2002",

doi = "10.1592/phco.22.1.97.33491",

language = "American English",

volume = "22",

pages = "97--101",

journal = "Pharmacotherapy",

issn = "0277-0008",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Major bleeding caused by warfarin in a genetically susceptible patient

AU - Bloch, Aharon

AU - Ben-Chetrit, Eldad

AU - Muszkat, Mordechai

AU - Caraco, Yoseph

PY - 2002

Y1 - 2002

N2 - A 90-year-old woman was hospitalized for gastrointestinal bleeding. Although she had been receiving only warfarin 5 mg/day, her international normalized ratio (INR) was 66. Warfarin was discontinued, and her INR fell to 3.7 after transfusion of fresh-frozen plasma. However, it rose again spontaneously to 7.5. Eleven days after the last dose of warfarin had been administered, it was still detectable in the patient's plasma, indicating that impaired warfarin clearance may have caused an enhanced anticoagulation effect. Genetic analysis of the cytochrome P450 (CYP) isoenzyme 2C9, which mediates the major deactivating pathway of S-warfarin, revealed that the patient was a compound heterozygote carrying two variant alleles: CYP2C9*2 and CYP2C9*3. The patient's enhanced sensitivity to warfarin 5 mg/day can be ascribed to decreased clearance of S-warfarin secondary to genetic alteration of the gene encoding CYP2C9, resulting in a life-threatening complication.

AB - A 90-year-old woman was hospitalized for gastrointestinal bleeding. Although she had been receiving only warfarin 5 mg/day, her international normalized ratio (INR) was 66. Warfarin was discontinued, and her INR fell to 3.7 after transfusion of fresh-frozen plasma. However, it rose again spontaneously to 7.5. Eleven days after the last dose of warfarin had been administered, it was still detectable in the patient's plasma, indicating that impaired warfarin clearance may have caused an enhanced anticoagulation effect. Genetic analysis of the cytochrome P450 (CYP) isoenzyme 2C9, which mediates the major deactivating pathway of S-warfarin, revealed that the patient was a compound heterozygote carrying two variant alleles: CYP2C9*2 and CYP2C9*3. The patient's enhanced sensitivity to warfarin 5 mg/day can be ascribed to decreased clearance of S-warfarin secondary to genetic alteration of the gene encoding CYP2C9, resulting in a life-threatening complication.

UR - http://www.scopus.com/inward/record.url?scp=0036138789&partnerID=8YFLogxK

U2 - 10.1592/phco.22.1.97.33491

DO - 10.1592/phco.22.1.97.33491

M3 - Article

C2 - 11794436

AN - SCOPUS:0036138789

SN - 0277-0008

VL - 22

SP - 97

EP - 101

JO - Pharmacotherapy

JF - Pharmacotherapy

IS - 1

ER -

Major bleeding caused by warfarin in a genetically susceptible patient

Abstract

Access to Document

Other files and links

Fingerprint

Cite this